Switzerland upgrades tests to boost detection of sartan impurities

By Nick Taylor

- Last updated on GMT

(Image: Getty/bluejayphoto)
(Image: Getty/bluejayphoto)

Related tags Sartan Therapeutic proteins regulatory regulatory approval

The Swiss Agency for Therapeutic Products revises the test it uses to assess whether sartan medicines are contaminated with nitrosamines.

Regulators around the world have paid close attention to the risk of nitrosamine contamination since a potential carcinogen, N-nitrosodimethylamine (NDMA), was found in batches of valsartan produced by Zhejiang Huahai Pharmaceutical last year. The regulatory investigations subsequently expanded to cover other drugs in the sartan class and contaminants related to NDMA.

Swissmedic recently improved its ability to protect patients from the contaminants by adopting an upgraded test method based on the use of gas chromatography–mass spectrometry. The regulator said the changes “further improve the sensitivity of testing for nitrosamine contamination​,” adding that the test is more robust than its predecessor.

Using the new test, Swissmedic can detect NDMA in most sartans down to levels of three parts per billion (PPB). The sole exception is candesartan, an angiotensin II receptor antagonist developed by AstraZeneca. The test can only detect NDMA in that sartan down to six PPB.

Swissmedic’s test can also detect and quantify N-nitrosodiethylamine (NDEA), a substance related to NDMA that was found in batches of valsartan Zhejiang Huahai produced before changing its manufacturing process in 2012.

Applied to NDEA, the new test is even more sensitive. The test detects NDEA down to two PPB in all sartans except candesartan. The limit of detection for the AstraZeneca-developed sartan is three PPB.

While Swissmedic thinks NDMA and NDEA can feasibly be spotted at those low levels, higher concentrations need to be present to quantitatively detect the contaminants with a certain level of accuracy and precision. The limit of quantification of the test ranges from five to 20 PPB, depending on the contaminant and sartan involved.

The adoption of the improved test is part of a long-running effort by the Swiss regulator to get on top of the threat posed by contaminated sartans. 

In July 2018, Swissmedic oversaw a recall of certain products that contain valsartan amid reports that some medicines were contaminated with a potentially carcinogenic impurity. Swissmedic followed up by testing samples of 10 valsartan-containing medicines that were outside of the scope of the recall.

Those tests found the sampled medicines were free from NMDA, enabling Swissmedic to move on to the assessment of other sartans. Late last year, Swissmedic revealed that it had found no evidence of contamination with NDMA in tests of more than 50 products that contained losartan, olmesartan, candesartan and irbesartan, active ingredients that have the tetrazole ring that makes valsartan susceptible to contamination.

Related news

Show more

Related products

A Guide Through the API Drug Development Pipeline

A Guide Through the API Drug Development Pipeline

Content provided by Lonza Small Molecules | 11-Jul-2023 | Insight Guide

With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.

Related suppliers

Follow us


View more